Zantac Lawsuit Update October 2026 — 847 Federal Claims Remain, the Latest Court Rulings and Who Can Still File
The Zantac litigation is in its final chapter in October 2026. Roughly 847 federal actions remain pending in MDL 2924 while plaintiffs await an Eleventh Circuit decision on the 2022 dismissal, Delaware's cases were thrown out in April 2026 and are under appeal, and most state claims have settled or been dismissed. New claims are still possible in some states within the statute of limitations.
- About 847 of 15,018 federal actions remain pending in MDL 2924, with the Eleventh Circuit appeal expected to be decided in the second half of 2026.
- In April 2026 Delaware threw out its remaining Zantac cases; plaintiffs appealed in May 2026.
- GSK paid up to $2.2 billion in October 2024 to resolve about 80,000 state-court cases, plus a $70 million whistleblower settlement.
- Every jury trial so far has sided with the drugmakers, including nine verdicts for Boehringer Ingelheim.
- New lawsuits may still be filed in some states, but many filing deadlines have passed since ranitidine left the market in 2020.
Where the Federal Litigation Stands
An MDL, or multidistrict litigation, gathers similar federal lawsuits before one judge. In February 2020 the Judicial Panel on Multidistrict Litigation consolidated federal Zantac cases as MDL No. 2924 in the Southern District of Florida. The suits claim ranitidine, Zantac's active ingredient, degraded into NDMA, a probable human carcinogen, causing bladder, esophageal, gastric, liver, pancreatic and other cancers.
The turning point came on December 28, 2022, when Judge Robin L. Rosenberg issued a 300-plus-page Daubert opinion excluding all of the plaintiffs' general-causation experts. As gatekeeper under the Daubert standard, the judge found the chemistry methodology unreliable, the epidemiological evidence too weak, and no ranitidine-specific studies proving the drug could cause cancer at therapeutic doses; about 14,000 federal cases were dismissed.
Plaintiffs appealed to the Eleventh Circuit, which heard argument on October 10, 2025 and is expected to rule in the second half of 2026. The Judicial Panel's September 1, 2026 report lists 847 actions still pending out of 15,018 total filed since 2020.
Delaware: From Trial-Ready to Dismissed
Delaware was the largest state-court battleground, holding more than 80,000 cases at its peak. In 2024 a Delaware judge cleared the plaintiffs' expert testimony for trial, but in July 2025 the Delaware Supreme Court reversed that decision as unreliable. Judge Francis J. Jones then granted summary judgment in April 2026 for the drug companies in all cases filed on or before December 1, 2025, writing that plaintiffs were not entitled to a mulligan. Plaintiffs appealed in May 2026, and GSK says it has no further Delaware cases pending. Judges in California and Illinois, by contrast, found similar expert evidence sufficient to reach a jury.
The Settlements That Resolved Most Cases
Most of the money in the Zantac litigation came from settlements, not verdicts. On October 9, 2024, GSK announced agreements with 10 plaintiff firms covering about 93 percent of its pending state-court cases, roughly 80,000 claims, for up to $2.2 billion in aggregate payments, with no admission of liability. GSK separately paid $70 million to settle the qui tam whistleblower complaint filed by Valisure, whose 2019 citizen petition first flagged NDMA in ranitidine. Terms of the state-court agreements were confidential.
Other makers followed. Pfizer agreed in May 2024 to resolve more than 10,000 state-court cases, with the Financial Times later reporting the payout at $200 million to $250 million, and settled two more Connecticut cases in September 2025 on undisclosed terms. Sanofi settled about 4,000 cases for more than $100 million. GSK also resolved the City of Baltimore and New Mexico Attorney General lawsuits.
Trial Results So Far Favor the Drugmakers
Every Zantac case that has reached a jury has ended in a defense verdict, including nine trials involving Boehringer Ingelheim. No jury has found that ranitidine caused a plaintiff's cancer, and the companies maintain there is no consistent or reliable evidence it increases any cancer risk.
For other pharmaceutical mass torts, see our updates on the hair relaxer lawsuits, the Ozempic litigation and the talc powder lawsuits use the same format.
Who Can Still File in October 2026
New Zantac lawsuits can still be filed by qualifying individuals, but the window is narrowing. Every state sets a statute of limitations, a filing deadline, and in many states the clock starts at diagnosis or when a person learns the injury may be tied to a product. Because ranitidine left the U.S. market in April 2020, many possible claims have already expired, though intake firms are still accepting new Zantac cancer cases subject to state-specific deadlines.
Compensation varies widely by case, and no reliable public per-case figures exist because most settlements are confidential. Most mass-tort firms handle these cases on a contingency fee basis, typically 33 to 40 percent of any recovery. This article is general information, not legal advice, and only a licensed attorney in your state can assess your deadline and eligibility. For plain-language explainers of mass-tort lawsuits, see the videos on Problem Solved.
What to Do If You Took Zantac and Got Cancer
If you used Zantac or generic ranitidine and were later diagnosed with cancer, gather your records now: pharmacy records, over-the-counter purchase receipts, pathology and biopsy reports, treatment records, and proof of lost income. Do not wait to check your deadline, because a missed statute of limitations ends a claim permanently. Bring everything to a mass-tort attorney for a free evaluation of whether your state deadline is still open.
Who Benefits From This — and Who Does Not
In October 2026 roughly 847 federal actions remain pending in MDL 2924 while plaintiffs await an Eleventh Circuit decision on the 2022 dismissal — expected in the second half of 2026 — and the Delaware cases dismissed in April 2026 are under appeal. In October 2024 GSK agreed to pay up to $2.2 billion in aggregate to resolve about 93 percent of its then-pending U.S. state-court cases, roughly 80,000 claims, with no admission of liability; per-person amounts were confidential.
Who benefits:
- People who took Zantac or generic ranitidine and were later diagnosed with cancer, in a state whose deadline is still open — Check your deadline now, gather pharmacy records, pathology and biopsy reports and treatment records, and bring everything to a mass-tort attorney for a free evaluation of whether your state deadline is still open.
- Plaintiffs whose cases are among the 847 pending federal actions — Their outcome turns on the Eleventh Circuit decision expected in the second half of 2026 and on the Delaware appeals — follow both instead of expecting a quick settlement.
- People who want a fast answer on whether they can still file — Most mass-tort firms handle these cases on contingency, typically 33 to 40 percent of any recovery, and intake firms are still accepting new Zantac cancer cases subject to state-specific deadlines.
Who does not benefit:
- People whose state statute of limitations has already expired since 2020 — Because ranitidine left the U.S. market in April 2020, many possible claims have already expired, and a missed statute of limitations ends a claim permanently.
- People with no ranitidine use or no cancer diagnosis — The article addresses people who took Zantac and got cancer; without both elements there is no Zantac case to evaluate.
- People expecting a guaranteed individual payout — No reliable public per-case figures exist because most settlements are confidential, and no jury has found that ranitidine caused a plaintiff’s cancer — every case that reached a jury ended in a defense verdict, including nine trials involving Boehringer Ingelheim.
Related reading: talc powder lawsuits.
Frequently Asked Questions
Is the Zantac lawsuit over?
No. The federal MDL was largely dismissed in 2022, but the Eleventh Circuit appeal is still pending with a decision expected in the second half of 2026, and plaintiffs have appealed the April 2026 Delaware dismissals. New cases can still be filed in some states within their statutes of limitations.
How much did GSK pay to settle Zantac lawsuits?
In October 2024 GSK agreed to pay up to $2.2 billion in aggregate to resolve about 93 percent of its then-pending U.S. state-court cases, roughly 80,000 claims, with no admission of liability. It separately paid $70 million to settle the whistleblower complaint filed by Valisure. Per-person amounts were confidential.
Why was Zantac taken off the market?
In April 2020 the FDA requested that all prescription and over-the-counter ranitidine products be withdrawn from the U.S. market. The agency was concerned that ranitidine could degrade into NDMA, a probable human carcinogen, over time or when exposed to heat. Valisure's 2019 testing found NDMA levels far above the FDA's acceptable daily intake limit of 96 nanograms.
Has anyone won a Zantac trial against the drugmakers?
No. Every Zantac cancer case that reached a jury has ended in a defense verdict, including nine trials involving Boehringer Ingelheim. No jury has found that ranitidine caused a plaintiff's cancer.
Can I still file a Zantac lawsuit in October 2026?
Possibly, depending on your state. The statute of limitations varies by state and often starts at diagnosis, so some deadlines have expired since ranitidine left the market in 2020 while others may still be open. Speak with a licensed attorney promptly to confirm your deadline.
Who still benefits from the Zantac lawsuit in October 2026 — and who does not?
People who took Zantac or generic ranitidine and were later diagnosed with cancer still benefit while their state deadline remains open, as do plaintiffs among the 847 pending federal actions awaiting the Eleventh Circuit decision in the second half of 2026. People whose deadline expired since 2020 do not benefit, nor do people with no ranitidine use or cancer diagnosis, nor anyone expecting a guaranteed individual payout — per-case amounts stayed confidential. First step: gather your records and have a licensed attorney in your state check your deadline promptly.